News Daily News Más Noticias Desalentadoras para los BRFs en el Tratamiento de Lesiones Infrapoplíteas L.A. McKeown October 26, 2015
News Conference News TCT 2015 Safety, Efficacy Endpoints Must Be Balanced in Clinical Trials October 13, 2015
News Conference News TCT 2015 Discussion Highlights Merits, Limitations of Small Trials Yael L. Maxwell October 13, 2015
News Conference News TCT 2015 BIOSOLVE-II: Novel Absorbable Scaffold Safe, Effective October 12, 2015
News Conference News TCT 2015 Leadership at Forefront of Cath Lab Operations Yael L. Maxwell October 11, 2015
News Daily News PCI Transradial podría atenuar los beneficios de la bivalirudina Todd Neale October 05, 2015
News Daily News RenalGuard Protects TAVR Patients Against AKI Better Than Does Standard Saline September 22, 2015
News Daily News RenalGuard Evita la LRA en Pacientes TAVR Mejor que una Solución Salina Estándar September 22, 2015
News Conference News ESC 2015 High-Sensitivity Troponin Assay Use Does Not Appear to Increase Diagnostic Procedures L.A. McKeown September 02, 2015
News Industry News Bayer Expands Finerenone Clinical Development Program with Three Phase III Studies for Finerenone in Patients with Diabetic Kidney Disease and Patients with Chronic Heart Failure August 31, 2015
News Daily News La Rehabilitación Cardíaca Post-IAM se asoció a una Mejor Supervivencia y Adherencia a la Medicación Leah Lawrence August 30, 2015
News Opinion Conversations in Cardiology Conversations in Cardiology: FFR in a Diagnostic-Only Lab and PCI Without On-site Surgery August 03, 2015
News Industry News Esperion Therapeutics Announces Positive Top-Line Phase 2 Results for ETC-1002 in Patients With Hypercholesterolemia and Hypertension July 28, 2015
News Daily News La FDA Aprueba un Fármaco contra la Insuficiencia Cardíaca que Beneficia la Supervivenia Todd Neale July 13, 2015
News Daily News FDA Approves Heart Failure Drug That Comes With Survival Benefit Todd Neale July 13, 2015
News Industry News Novartis' new heart failure medicine LCZ696 approved by FDA to reduce risk of cardiovascular death and heart failure hospitalization; now called Entresto™ (sacubitril-valsartan) July 07, 2015